Sunshine Biopharma Inc. Capital Expenditures
Sunshine Biopharma Inc. (SBFM) reported Capital Expenditures of $12.14 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $7.01K, a 95.62% decline year-over-year.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $5.13K, a 31.52% decline year-over-year.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was -$1.04K, a 101.01% decline year-over-year.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $8.04K, a 98.44% decline year-over-year.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $174.49K, a 89.47% decline from fiscal 2024.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $1.66M, a 1914.63% increase from fiscal 2023.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $82.25K, a 57.60% decline from fiscal 2022.
- Sunshine Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $193.98K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $12.14K 10-Q · filed 2026-08-13 | $11.11K derived: sum of 3 quarters · filed 2026-08-13 | $19.14K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $5.13K 10-Q · filed 2026-05-13 | $4.09K derived: sum of 2 quarters · filed 2026-05-13 | $12.13K derived: sum of 3 quarters · filed 2026-05-13 | $172.13K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $7.00K derived: sum of 2 quarters · filed 2026-04-03 | $167.00K derived: sum of 3 quarters · filed 2026-08-13 | $174.49K 10-K · filed 2026-04-03 |
| 2025-09-30 | $8.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $168.04K derived: sum of 2 quarters · filed 2026-08-13 | $175.53K 10-Q · filed 2025-11-13 | $278.13K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $167.49K 10-Q · filed 2026-08-13 | $270.09K derived: sum of 3 quarters · filed 2026-08-13 | $787.10K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $7.49K 10-Q · filed 2026-05-13 | $110.09K derived: sum of 2 quarters · filed 2026-05-13 | $627.10K derived: sum of 3 quarters · filed 2026-05-13 | $1.60M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $102.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $619.61K derived: sum of 2 quarters · filed 2026-04-03 | $1.59M derived: sum of 3 quarters · filed 2026-04-03 | $1.66M 10-K · filed 2026-04-03 |
| 2024-09-30 | $517.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.49M derived: sum of 2 quarters · filed 2025-11-13 | $1.55M 10-Q · filed 2025-11-13 | $1.17M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $974.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.04M 10-Q · filed 2025-08-12 | $655.09K derived: sum of 3 quarters · filed 2025-08-12 | $664.72K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $62.94K 10-Q · filed 2025-05-15 | -$319.43K derived: sum of 2 quarters · filed 2025-05-15 | -$309.79K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$382.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | -$372.73K derived: sum of 2 quarters · filed 2025-04-01 | $82.25K 10-K · filed 2025-04-01 | |
| 2023-09-30 | $9.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $464.61K 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $454.98K 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $193.98K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $193.98K derived: sum of 2 quarters · filed 2024-03-28 | $193.98K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-04 | $0.00 10-K · filed 2023-04-04 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $391.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.19K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $800.00 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $860.00 10-K · filed 2021-03-30 | |||
| 2018-12-31 | $18.85K 10-K · filed 2020-05-01 | |||
| 2017-12-31 | $3.72K 10-K · filed 2019-04-12 | |||
| 2016-12-31 | $3.44K 10-K · filed 2018-04-02 | |||
| 2016-06-30 | $2.34K 10-Q · filed 2016-08-16 | |||
| 2015-12-31 | $4.79K 10-K · filed 2017-04-17 | |||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-16 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |